Abstract
1-1-2D, a novel human monoclonal antibody (MAb) raised against cervical cancer, was examined for its immunohistochemical reactivity with ovarian cancer. Six of 10 ovarian cancer cell lines showed positive staining, while 3 of 5 cervical cancer cell lines were positive. Among tumor tissues, 15 of 18 (83%) ovarian serous cystadenocarcinomas and 10 of 12 (83%) ovarian clear cell adenocarcinomas were positive. We also performed immunohistochemical staining of the same cancer specimens with OC 125 and compared their reactivity. The frequency of positivity was similar, but the reactivity of the two MAbs was different. 1-1-2D stained the apical surface of the glandular epithelial cells and secretory products of the gland. On the other hand, OC 125 stained the cytoplasm as well as the plasma membrane of the glandular epithelial cells. These results suggest that 1-1-2D MAb recognizes a different antigen from that recognized by OC 125.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Finkler NJ, Muto MG, Kassis AI, Weadock K, Tumesh SS, Zurawski VJ, Knapp RC (1989) Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer. Gynecol Oncol 34:339–344
Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB (1983) Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 79:98–104
Kennedy AW, Biscotti CV, Hart WR, Webster KD (1989) Ovarian clear cell adenocarcinoma. Gynecol Oncol 32:342–349
Kikuchi Y, Kizawa I, Oomori K, Miyauchi M, Kita T, Sugita M, Tenjin Y, Kato K (1987) Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. Cancer Res 47:592–596
Koelma IN, Nap M, van Steenis GJ, Fleuren GJ (1988) Tumor markers for ovarian cancer. Am J Clin Pathol 90:391–396
Komori S, Yamasaki N, Shigeta M, Isojima S, Watanabe T (1988) Production of heavy-chain class-switch variants of human monoclonal antibody by recombinant DNA technology. Clin Exp Immunol 71:508–516
Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC (1987) CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 69:223–227
Morikawa Y, Kawai M, Kano T, Kikkawa F, Oguchi H, Nakashima N, Ishizuka T, Furuhashi Y, Hattori S, Kuzuya K, Ohta M, Arii Y, Tomoda Y (1993) Clinical remission criteria for epithelial carcinoma of the ovary. Gynecol Oncol 48:342–438
Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR, Bast RC (1986) The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 155:56–60
O'Brien MER, Schofield JB, Tan S, Fryatt I, Fisher C, Wiltshaw E (1993) Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 49:250–254
Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley H (1986) A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma: a gynecologic oncology group study. Cancer 57:1725–1730
Rubin SC, Hoskins WJ, Hakes TB, Markman M, Reichman BS, Chapman D, Lewis JL (1989) Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 160:667–671
Rubin SC, Kostakoglu L, Divgi C, Federici MG, Finstad CL, Lloyd KO, Larson SM, Hoskins WJ (1993) Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gynecol Oncol 51:61–66
Sugiura M, Goto S, Saito M, Kato S, Hattori S, Tomoda Y (1988) Establishment and characterization of three new human gestational choriocarcinoma cell lines. Acta Obstet Gynaecol Jpn 40:1447–1454
Sutton GP, Stehman FB, Einhorn LH, Roth LM, Blessing JA, Ehrlich CE (1989) Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7:223–229
Yabushita H, Nakagawa Y, Sawaguchi K, Noguchi M, Ishihara M (1988) Differences in the mechanisms of production and release of SCC-Ag and CEA from an established uterine cervical carcinoma cell line (AMCC-1). Asia-Oceania J Obstet Gynaecol 14:493–50
Yamamuro O, Goto S, Mano H, Saito M, Watanabe M, Nagoya T, Tomoda Y (1994) Human monoclonal antibody [1-1-2D] against cancer of the uterine cervix. Hybridoma 13:131–137
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nakanishi, T., Okamoto, T., Nawa, A. et al. A novel human monoclonal antibody against cervical cancer: its immunoreactivity with normal tube and ovary and with ovarian tumor tissue. Arch Gynecol Obstet 256, 177–184 (1995). https://doi.org/10.1007/BF00634489
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00634489